Characteristics of Patients Newly Prescribed IDegLira in U.S. Real-World Practice
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-2285-pub
Abstract: Background: IDegLira, a fixed-ratio combination of a basal insulin (BI), insulin degludec, and liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1), was approved by the FDA in Q4 2016 for the treatment of type 2 diabetes… read more here.
Keywords: self novo; prescribed ideglira; glp; inj ... See more keywords